Plus Therapeutics Initiates Treatment in ReSPECT-LM Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV), a pioneering clinical-stage pharmaceutical company, has announced a significant advancement in the fight against leptomeningeal metastases (LM) with the commencement of patient treatment in its ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re186 obisbemeda). This innovative trial aims to determine the optimal dosing regimen for patients suffering from this severe complication of cancer.
Trial Objectives and Design
The ReSPECT-LM dose optimization trial is built upon encouraging findings from a prior Phase 1 single-dose escalation study. This earlier research demonstrated the potential effectiveness of REYOBIQ in treating LM, a rare condition that significantly complicates the care of patients with advanced cancer. The current trial is strategically aligned with the FDA's Project Optimus, focusing on establishing a dosing regimen that balances efficacy and safety.
Enrollment Process and Expectations
Dr. Andrew Brenner, a key figure in this initiative, expressed optimism regarding the trial's potential, citing the rapid enrollment process expected due to the urgent need for effective therapies for LM. With no FDA-approved options currently available, the team anticipates that all necessary patients and doses in Cohort 1 will be enrolled by the conclusion of this year.
Trial Impact and Promising Results
The ReSPECT-LM trial is designed not only to assess safety but also to identify both the maximum tolerated dose and the minimum effective dose of REYOBIQ. In prior studies, a single dose showed that over 80% of patients experienced a significant reduction in LM tumor cells within the cerebrospinal fluid, highlighting the therapy's strong potential for extending patient survival.
Upcoming Presentations and Meetings
The company plans to share further data from these studies at the upcoming SNO/ASCO CNS Metastases Conference. Expectations are set to outline the clinical development plan and facilitate discussions regarding future registrational trials with the FDA.
Understanding Leptomeningeal Metastases
Leptomeningeal metastases occur in approximately 5% of patients with metastatic cancer and pose a grave challenge due to their impact on the central nervous system. Commonly stemming from breast, lung, and melanoma cancers, LM is associated with a median survival of only 2-6 months. This underscores the pressing demand for more effective treatments that can significantly improve patient outcomes.
Innovations in REYOBIQ™ Treatment
REYOBIQ™ represents a novel approach in injectable radiotherapy. Specifically designed for central nervous system tumors, this innovative treatment method administers high-dose radiation directly to target cancerous tissues, minimizing off-target effects and improving overall patient health prospects. It employs rhenium-186, which is praised for its suitable half-life and effective emission properties for both treatment and imaging.
Support from CPRIT
The trial's success is bolstered by funding from the Cancer Prevention & Research Institute of Texas (CPRIT), which highlights the importance of public initiatives in facilitating groundbreaking cancer research. The support reflects a significant investment in developing novel therapies that aim to change the landscape of cancer treatment.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics is dedicated to advancing targeted radiotherapeutics for challenging CNS cancers. Their innovative focus uses a combination of image-guided radiation and sophisticated drug delivery mechanisms, with active trials looking at multiple cancers including LM and recurrent glioblastoma. The company prides itself on establishing strategic partnerships to enhance the development and accessibility of its therapies.
Frequently Asked Questions
What is the purpose of the ReSPECT-LM trial?
The ReSPECT-LM trial aims to optimize dosing of REYOBIQ to maximize efficacy and safety for patients with leptomeningeal metastases.
Who is leading the ReSPECT-LM trial?
Dr. Andrew Brenner, an esteemed professor and researcher, is leading the trial at the Mays Cancer Center.
How does REYOBIQ™ work?
REYOBIQ™ delivers targeted radiation directly to CNS tumors, efficiently treating cancer while minimizing damage to surrounding healthy tissues.
What is the survival rate for patients with leptomeningeal metastases?
Median survival for patients with leptomeningeal metastases is generally between 2-6 months, emphasizing the need for effective therapies.
What support has Plus Therapeutics received for their research?
Plus Therapeutics has received substantial funding from the Cancer Prevention & Research Institute of Texas (CPRIT) to support their innovative cancer research initiatives.
